Ozempic vs Wegovy: What's the Difference?

If you've spent any time researching GLP-1s, you've probably noticed that Ozempic and Wegovy come up in almost every conversation — sometimes interchangeably, sometimes as if they're rivals. The truth is simpler than the marketing makes it look.

Ozempic and Wegovy are the same drug. Both are semaglutide, both made by Novo Nordisk, both injected once a week, both work through identical mechanisms. What's different is the label on the box, the dose ceiling, and how insurance treats them.

They are literally the same molecule

Pull up the FDA prescribing information for either pen and you'll find the exact same active ingredient: semaglutide, a GLP-1 receptor agonist engineered to mimic the gut hormone GLP-1 with a half-life of about a week.

The pens are also nearly identical hardware. Same auto-injector design, same once-weekly subcutaneous injection, same instructions for use. If you're ever curious, the molecule on a Wegovy box is the same molecule on an Ozempic box, made in the same facilities, packaged differently.

For the broader picture of how the molecule itself works, see the semaglutide pillar.

What's different: indication and dose ceiling

The FDA approves drugs for specific indications — meaning specific medical conditions backed by specific clinical trials. Novo Nordisk ran two different trial programs for semaglutide, and the FDA gave each its own brand and its own label.

Ozempic's titration tops out at 2.0 mg weekly. Wegovy goes up to 2.4 mg weekly. That 0.4 mg difference is small but meaningful — the STEP-1 trial that produced the famous 14.9% mean weight loss number was specifically run at 2.4 mg.

For the full step-by-step ramp on either brand, see semaglutide dosing schedule.

The insurance reality

This is where the two brands diverge most dramatically — and where most patients actually feel the difference.

• Ozempic is covered by most US insurance plans for patients with a type 2 diabetes diagnosis. Copays of $25–$50/month are common with commercial insurance.
• Wegovy is covered far less reliably. Many plans exclude weight-loss medications entirely. Even when it's covered, prior authorizations are common and BMI thresholds (usually ≥ 30, or ≥ 27 with a comorbidity) apply.

Without insurance, both pens list around $1,000–1,350/month in 2025. That's why off-label Ozempic prescriptions for weight loss became a phenomenon — and why the compounded semaglutide market exploded when Wegovy hit the FDA shortage list.

What about the off-label question?

For a stretch of 2022–2024, prescribers routinely wrote Ozempic prescriptions for patients without diabetes who wanted the weight-loss effect. This is off-label prescribing — legal, common, but increasingly scrutinized.

Two things have changed:

1. Wegovy supply has improved. The acute shortage that pushed everyone toward Ozempic eased through 2024–2025.
2. Insurers have wised up. Many plans now require a confirmed T2D diagnosis (with lab evidence) before approving Ozempic, specifically to prevent off-label weight-loss use on the cheaper-tier formulary.

If your goal is weight loss and you don't have diabetes, Wegovy is the on-label choice. Whether your insurance will cover it is a different question entirely.

When patients switch between them

The most common scenarios we hear:

• Wegovy was unavailable, started on Ozempic, now switching to Wegovy as supply normalizes (and to access the higher 2.4 mg ceiling).
• Insurance changed. A new employer plan covers one but not the other.
• Hit a plateau on 2.0 mg Ozempic and want the extra 0.4 mg headroom that Wegovy offers.
• Diabetes diagnosis added or removed, changing which brand the insurer will cover.

Switching is straightforward because the molecule is identical — usually no washout period, just continue at the same milligram dose on the new brand. Full playbook in switching from Ozempic to Wegovy.

Rybelsus is a different conversation

While we're here: Rybelsus is also semaglutide, but in oral tablet form. It's approved for type 2 diabetes only, taken daily on an empty stomach, and has notably lower bioavailability — about 1% of the oral dose is absorbed, which is why the milligrams (3, 7, 14) look so much higher than the injectable doses.

Rybelsus is rarely the first choice for weight loss because the absorbed dose is small and the daily routine is fussy (must be taken first thing in the morning with no more than 4 oz of water, then nothing else for 30 minutes).

What the difference does not mean

A few myths worth dispelling:

• Wegovy is not "stronger" semaglutide. It's the same molecule, just titrated to a higher dose ceiling.
• Ozempic does not "treat diabetes better" than Wegovy. If you took 2.0 mg Wegovy for diabetes, it would behave identically to 2.0 mg Ozempic.
• The pens are not interchangeable at the pharmacy. Even though the drug is identical, your pharmacist can only fill what's on the prescription. A switch requires a new prescription.
• The side effect profile is the same. Nausea, constipation, and the rest of the GI lineup hit users on both brands at similar rates, with severity tracking the dose more than the label.

How to think about the choice

If you have type 2 diabetes and your insurance covers Ozempic, that's almost always the path of least resistance.

If your goal is weight loss, you don't have diabetes, and you have access to Wegovy through insurance or willing-to-pay-cash, Wegovy is the on-label, higher-ceiling option.

If neither is covered and you're paying out of pocket, the compounded market enters the conversation — but that comes with its own homework. Start with is compounded semaglutide safe? before going that route.

Related questions

• Switching from Ozempic to Wegovy (or vice versa)
• Semaglutide dosing schedule: week by week
• Mounjaro vs Zepbound: same molecule, different brand